Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension

American Journal of Hypertension

Volumn 27, Issue 8, 2014, Pages 1024-1032

  Leenen, Frans H H ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Aldosterone; Angiotensin II; Blood pressure; Brain; Hypertension; Sympathetic activity

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALDOSTERONE; ANGIOTENSIN II;

BRAIN CHEMISTRY; HUMAN; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN II; BRAIN CHEMISTRY; HUMANS; HYPERTENSION; NEUROTRANSMITTER AGENTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84905837165     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu066     Document Type: Article

References (88)

1. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103: 17985-17990.
2. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 2011; 57: 880-886.
3. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-773.
4. Iliescu R, Irwin ED, Georgakopoulos D, Lohmeier TE. Renal responses to chronic suppression of central sympathetic outflow. Hypertension 2012; 60: 749-756.
5. Wright JW, Roberts KA, Stubley LA, Hanesworth JM, Harding JW. Hypothalamic angiotensin release in response to AII or glutamic acid stimulation of the SFO in rats. Brain Res Bull 1993; 31: 649-654.
6. Cato MJ, Toney GM. Angiotensin II excites paraventricular nucleus neurons that innervate the rostral ventrolateral medulla: an in vitro patch-clamp study in brain slices. J Neurophysiol 2005; 93: 403-413.
7. Li DP, Chen SR, Pan HL. Angiotensin II stimulates spinally projecting paraventricular neurons through presynaptic disinhibition. J Neurosci 2003; 23: 5041-5049.
8. Wang G, Anrather J, Glass MJ, Tarsitano MJ, Zhou P, Frys KA, Pickel VM, Iadecola C. Nox2, Ca2+, and protein kinase C play a role in angiotensin II-induced free radical production in nucleus tractus solitarius. Hypertension 2006; 48: 482-489.
9. Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 2004; 95: 210-216.
10. Richards EM, Raizada MK, Gelband CH, Sumners C. Angiotensin II type 1 receptor-modulated signaling pathways in neurons. Mol Neurobiol 1999; 19: 25-41.
11. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009; 302: 148-158.
12. Chen Q, Pan HL. Signaling mechanisms of angiotensin II-induced attenuation of GABAergic input to hypothalamic presympathetic neurons. J Neurophysiol 2007; 97: 3279-3287.
13. Li DP, Pan HL. Angiotensin II attenuates synaptic GABA release and excites paraventricular-rostral ventrolateral medulla output neurons. J Pharmacol Exp Ther 2005; 313: 1035-1045.
14. Zhu DN, Moriguchi A, Mikami H, Higaki J, Ogihara T. Central amino acids mediate cardiovascular response to angiotensin II in the rat. Brain Res Bull 1998; 45: 189-197.
15. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Is aldosterone synthesized within the rat brain? Am J Physiol 2005; 288: E342-E346.
16. Huang BS, Ahmadi S, Ahmad M, White RA, Leenen FH. Central neuronal activation and pressor responses induced by circulating ANG II: role of the brain aldosterone-"ouabain" pathway. Am J Physiol 2010; 299: H422-H430.
17. Wang HW, Amin MS, El-Shahat E, Huang BS, Tuana BS, Leenen FH. Effects of central sodium on epithelial sodium channels in rat brain. Am J Physiol 2010; 299: R222-R233.
18. Xue B, Zhang Z, Johnson RF, Johnson AK. Sensitization of slow pressor angiotensin II (Ang II)-initiated hypertension: induction of sensitization by prior Ang II treatment. Hypertension 2012; 59: 459-466.
19. Ye P, Kenyon CJ, MacKenzie SM, Seckl JR, Fraser R, Connell JM, Davies E. Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 2003; 144: 3321-3328.
20. Amin MS, Wang HW, Reza E, Whitman SC, Tuana BS, Leenen FH. Distribution of epithelial sodium channels and mineralocorticoid receptors in cardiovascular regulatory centers in rat brain. Am J Physiol 2005; 289: R1787-R1797.
21. Han F, Ozawa H, Matsuda K, Nishi M, Kawata M. Colocalization of mineralocorticoid receptor and glucocorticoid receptor in the hippocampus and hypothalamus. Neurosci Res 2005; 51: 371-381.
22. Moisan MP, Seckl JR, Edwards CR. 11 beta-Hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 1990; 127: 1450-1455.
23. Zhang ZH, Kang YM, Yu Y, Wei SG, Schmidt TJ, Johnson AK, Felder RB. 11beta-Hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension 2006; 48: 127-133.
24. Chen J, Gomez-Sanchez CE, Penman A, May PJ, Gomez-Sanchez E. Expression of mineralocorticoid and glucocorticoid receptors in preautonomic neurons of the rat paraventricular nucleus. Am J Physiol 2014; 306: R328-R340.
25. Ito K, Hirooka Y, Sunagawa K. Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload. J Hypertens 2010; 28: 1449-1458.
26. Miller RL, Wang MH, Gray PA, Salkoff LB, Loewy AD. ENaCexpressing neurons in the sensory circumventricular organs become c-Fos activated following systemic sodium changes. Am J Physiol 2013; 305: R1141-R1152.
27. Teruyama R, Sakuraba M, Wilson LL, Wandrey NE, Armstrong WE. Epithelial Na sodium channels in magnocellular cells of the rat supraoptic and paraventricular nuclei. Am J Physiol 2012; 302: E273-E285.
28. Yamada H, Ihara N, Takahashi H, Yoshimura M, Sano Y. Distribution of the endogenous digitalis-like substance (EDLS)-containing neurons labeled by digoxin antibody in hypothalamus and three circumventricular organs of dog and macaque. Brain Res 1992; 584: 237-243.
29. Yamada H, Naruse M, Naruse K, Demura H, Takahashi H, Yoshimura M, Ochi J. Histological study on ouabain immunoreactivities in the mammalian hypothalamus. Neurosci Lett 1992; 141: 143-146.
30. Yoshika M, Komiyama Y, Takahashi H. An ouabain-like factor is secreted from immortalized hypothalamic cells in an aldosteronedependent manner. Neurochem Int 2011; 59: 104-108.
31. Wang H, Huang BS, Leenen FH. Brain sodium channels and ouabainlike compounds mediate central aldosterone-induced hypertension. Am J Physiol 2003; 285: H2516-H2523.
32. Huang BS, Zheng H, Tan J, Patel KP, Leenen FH. Regulation of hypothalamic renin-angiotensin system and oxidative stress by aldosterone. Exp Physiol 2011; 96: 1028-1038.
33. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. Am J Physiol 2008; 294: H1067-H1074.
34. Gabor A, Leenen FH. Mechanisms in the PVN mediating local and central sodium-induced hypertension in Wistar rats. Am J Physiol 2009; 296: R618-R630.
35. Huang BS, Leenen FH. Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain ANG II. Am J Physiol 1996; 270: H275-H280.
36. Van Huysse JW, Hou X. Pressor response to CSF sodium in mice: mediation by a ouabain-like substance and renin-angiotensin system in the brain. Brain Res 2004; 1021: 219-231.
37. Davern PJ, Head GA. Fos-related antigen immunoreactivity after acute and chronic angiotensin II-induced hypertension in the rabbit brain. Hypertension 2007; 49: 1170-1177.
38. Hendel MD, Collister JP. Contribution of the subfornical organ to angiotensin II-induced hypertension. Am J Physiol 2005; 288: H680-H685.
39. Lob HE, Schultz D, Marvar PJ, Davisson RL, Harrison DG. Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension 2013; 61: 382-387.
40. Wei SG, Yu Y, Zhang ZH, Felder RB. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol 2009; 296: H1425-H1433.
41. Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 2011; 92: 401-408.
42. Gabor A, Leenen FHH. Central mineralocorticoid receptors and the role of Ang II and glutamate in the PVN of rats with Ang II-induced hypertension. Hypertension 2013; 61: 1083-1090.
43. Huang BS, White RA, Ahmad M, Leenen FHH. Role of brain corticosterone and aldosterone in central angiotensin II-induced hypertension. Hypertension 2013; 62: 564-571.
44. Xue B, Beltz TG, Yu Y, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK. Central interactions of aldosterone and angiotensin II in aldosterone and angiotensin II-induced hypertension. Am J Physiol 2011; 300: H555-H564.
45. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J Clin Invest 1979; 64: 145-154.
46. Parker RB, Yates CR, Laizure SC, Weber KT. P-Glycoprotein modulates aldosterone plasma disposition and tissue uptake. J Cardiovasc Pharmacol 2006; 47: 55-59.
47. Huang BS, White RA, Leenen FHH. Aldosterone-salt Hypertension depends on the SFO, central aldosterone synthase and MR specifically in the PVN. Hypertension 2013; 62: A441.
48. Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 4756-4761.
49. Leenen FHH. The central role of the brain aldosterone-"ouabain" pathway in salt sensitive hypertension. Biochimica Biophysica Acta 2010; 1082: 1132-1139.
50. Stocker SD, Monahan KD, Browning KN. Neurogenic and sympathoexcitatory actions of NaCl in hypertension. Curr Hypertens Rep 2013; 15: 538-546.
51. Oparil S, Sripairojthikoon W, Wyss JM. The renal afferent nerves in the pathogenesis of hypertension. Can J Physiol Pharmacol 1987; 65: 1548-1558.
52. Phillips JK. Pathogenesis of hypertension in renal failure: role of the sympathetic nervous system and renal afferents. Clin Exp Pharmacol Physiol 2005; 32: 415-418.
53. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol 2010; 298: R245-R253.
54. Chan RK, Chan YS, Wong TM. Electrophysiological properties of neurons in the rostral ventrolateral medulla of normotensive and spontaneously hypertensive rats. Brain Res 1991; 549: 118-126.
55. Matsuura T, Kumagai H, Kawai A, Onimaru H, Imai M, Oshima N, Sakata K, Saruta T. Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 2002; 40: 560-565.
56. Wang JM, Veerasingham SJ, Tan J, Leenen FH. Effects of high salt intake on brain AT1 receptor densities in Dahl rats. Am J Physiol 2003; 285: H1949-H1955.
57. Xia H, Sriramula S, Chhabra KH, Lazartigues E. Brain angiotensinconverting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Circ Res 2013; 113: 1087-1096.
58. Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JM, Sullivan MN, Earley S, Danser AH, Ichihara A, Feng Y. Neuron-specific (pro)renin receptor knockout prevents the development of salt-sensitive hypertension. Hypertension 2014; 63: 316-323.
59. Ye S, Zhong H, Yanamadala S, Campese VM. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension 2006; 48: 309-315.
60. Fujita M, Fujita T. The role of CNS in salt-sensitive hypertension. Curr Hypertens Rep 2013; 15: 390-394.
61. Huang BS, White RA, Bi L, Leenen FH. Central infusion of aliskiren prevents sympathetic hyperactivity and hypertension in Dahl salt-sensitive rats on high salt intake. Am J Physiol 2012; 302: R825-R832.
62. Gabor A, Leenen FH. Cardiovascular effects of angiotensin II and glutamate in the PVN of Dahl salt-sensitive rats. Brain Res 2012; 1447: 28-37.
63. Ito S, Hiratsuka M, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptors support arterial pressure in Dahl salt-sensitive rats. Hypertension 2003; 41: 744-750.
64. Blaustein MP, Leenen FH, Chen L, Golovina VA, Hamlyn JM, Pallone TL, Van Huysse JW, Zhang J, Wier WG. How NaCl raises blood pressure: a new paradigm for the pathogenesis of salt-dependent hypertension. Am J Physiol 2012; 302: H1031-H1049.
65. Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in saltinduced hypertension in Dahl salt-sensitive rats. Am J Physiol 2009; 296: R994-R1000.
66. Wang H, Leenen FH. Brain sodium channels mediate increases in brain "ouabain" and blood pressure in Dahl S rats. Hypertension 2002; 40: 96-100.
67. Huang BS, Van Vliet BN, Leenen FH. Increases in CSF [Na+] precede the increases in blood pressure in Dahl S rats and SHR on a high-salt diet. Am J Physiol Heart Circ Physiol 2004; 287: H1160-H1166.
68. Nakamura K, Cowley AW Jr. Sequential changes of cerebrospinal fluid sodium during the development of hypertension in Dahl rats. Hypertension 1989; 13: 243-249.
69. Gomez-Sanchez EP, Gomez-Sanchez CM, Plonczynski M, Gomez-Sanchez CE. Aldosterone synthesis in the brain contributes to Dahl salt-sensitive rat hypertension. Exp Physiol 2010; 95: 120-130.
70. Gomez-Sanchez EP, Samuel J, Vergara G, Ahmad N. Effect of 3beta-hydroxysteroid dehydrogenase inhibition by trilostane on blood pressure in the Dahl salt-sensitive rat. Am J Physiol 2005; 288: R389-R393.
71. Huang BS, Leenen FH. Blockade of brain "ouabain" prevents sympathoexcitatory and pressor responses to high sodium in SHR. Am J Physiol 1996; 271: H103-H108.
72. Huang BS, Leenen FH. Brain "ouabain" and angiotensin II in salt sensitive hypertension in spontaneously hypertensive rats. Hypertension 1996; 28: 1005-1012.
73. Ito K, Hirooka Y, Sunagawa K. Acquisition of brain Na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload. Circ Res 2009; 104: 1004-1011.
74. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23: 1052-1060.
75. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73: 913-999.
76. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009; 54: 375-385.
77. Leenen FHH. Cardiovascular consequences of sympathetic hyperactivity. Can J Cardiol 1999; 15: 2A-7A.
78. Liang B, Leenen FHH. Prevention of salt induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. J Cardiovasc Pharmacol 2008; 51: 457-466.
79. Leenen FHH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central AT1 receptor blockade. Hypertension 2001; 37: 981-984.
80. Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol 2006; 290: H1706-H1712.
81. Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Vongpatanasin W. Spironolactone prevents chlorthalidone induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012; 60: 319-325.
82. Ruzicka M, Floras J, McReynolds AG, Coletta E, Haddad H, Davies R, Leenen FHH. Do high doses of AT1-receptor blockers attenuate central sympathetic outflow in humans with chronic heart failure? Clin Sci 2013; 124: 589-595.
83. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J 2004; 25: 1974-1978.
84. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA; HEAAL Investigators. Effects of high-dose versus lowdose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009; 374: 1840-1848.
85. Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, Felder RB. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol 2001; 281: H2241-H2251.
86. Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 2009; 94: 1361-1366.
87. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension 2010; 55: 1217-1223.
88. Gabor A, Leenen FHH. Central neuromodulatory pathways regulating sympathetic activity in hypertension. J Applied Physiol 2012; 113: 1294-1303.